Secretin

Mechanism

A natural gut hormone used as a diagnostic tool to test how well the pancreas is functioning and to help diagnose gastrinomas (gastrin-producing tumors). When injected, it stimulates the pancreas to release bicarbonate and fluid — if the pancreas is diseased, this response is diminished. Also gained public attention when studied as a potential autism treatment, but clinical trials showed no benefit.

Effects

## Gastrointestinal/Pancreatic System [Tier 1 - FDA-Approved Diagnostic, Extensive Human Data] - 27-amino-acid peptide hormone produced by S-cells in the duodenal mucosa in response to acidic chyme - Stimulates pancreatic ductal bicarbonate and water secretion, neutralizing gastric acid entering the duodenum - Stimulates hepatic bile flow (choleretic effect) — increases bile volume and bicarbonate content - Inhibits gastric acid secretion and gastric motility (negative feedback loop with gastrin) - FDA-approved as a diagnostic agent for pancreatic exocrine function (secretin stimulation test) and for Zollinger-Ellison syndrome ## Hepatobiliary System [Tier 1 - Human Data] - Stimulates cholangiocyte secretion, promoting bile flow through the common bile duct - Used diagnostically with MRCP (secretin-enhanced MRCP) to visualize pancreatic duct anatomy and detect obstruction - May improve bile duct drainage in post-cholecystectomy patients with biliary dyskinesia (limited evidence) ## Central Nervous System [Tier 2 - Mixed Human Data] - Secretin receptors are expressed in brain (cerebellum, hippocampus, amygdala) - Early controversial studies suggested benefit in autism spectrum disorder (Janet Horvath case reports, 1998) - Subsequent controlled trials (large NIH-funded RCT) showed NO significant benefit for autism core symptoms - May have neuromodulatory effects independent of autism: anxiolytic properties observed in animal models - Ongoing research into secretin's role in social behavior and stress response ## Endocrine System [Tier 1 - Human Data] - Stimulates insulin release (minor, glucose-dependent) — potentiates GLP-1 signaling - Inhibits glucagon secretion - Promotes satiety through vagal afferent signaling - Recent research suggests secretin acts as a "gut-brain-brown fat axis" hormone, stimulating thermogenesis ## Metabolic System [Tier 2 - Emerging Human Data] - Activates brown adipose tissue (BAT) thermogenesis through a gut-brain-BAT axis (Li et al., Cell 2018) - Meal-induced secretin release promotes postprandial satiety via brain activation patterns on fMRI - May increase energy expenditure through BAT activation — potential metabolic/weight management implications - This is an emerging area of research that could reposition secretin as a metabolic peptide

Practitioner Guide

## Clinical Context Secretin is primarily a diagnostic agent in mainstream medicine. Its use in peptide therapy clinics is uncommon. Patients asking about secretin are typically: (a) parents of autistic children who read the 1998 case reports, (b) individuals with pancreatic insufficiency, or (c) biohackers interested in the brown fat/thermogenesis research. ## FDA-Approved Uses - Secretin stimulation test: 0.2mcg/kg IV bolus, then measure pancreatic bicarbonate output - Secretin-enhanced MRCP: 0.2mcg/kg IV to distend pancreatic duct for imaging - Zollinger-Ellison syndrome diagnosis: measure gastrin response to secretin ## Off-Label/Investigational - Autism: NOT recommended. Multiple controlled trials (including NIH-funded) showed no benefit. The initial excitement was based on anecdotal case reports that did not replicate. - Pancreatic insufficiency support: theoretical, but exogenous pancreatic enzymes (Creon) are the standard approach - Brown fat activation: fascinating preclinical data but no clinical protocol exists ## Dosing (Diagnostic) - 0.2mcg/kg IV (synthetic human secretin — ChiRhoStim or SecreFlo) - Not typically used SC or IM in clinical practice - Not available in standard peptide therapy formulations ## What to Tell Patients - If asking about autism: the evidence does not support secretin for ASD. Redirect to evidence-based interventions. - If asking about metabolic/thermogenesis: this is promising research but there are no clinical protocols. MOTS-c, exercise, and cold exposure are more practical BAT activation strategies. - If asking about digestive support: BPC-157 orally, or simply pancreatic enzyme replacement, are more practical approaches.

Evidence

• Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitis

  M. Tariq et al. (2013) — Pancreas — PMID: 23711627

  Among 116 patients evaluated for suspected early chronic pancreatitis with normal imaging, secretin pancreatic function testing showed 82% sensitivity, 86% specificity, and a 97% negative predictive value for ruling out early chronic pancreatitis on long-term follow-up.

  moderate

Research Summary

## Tier 1 — Human Clinical Data - Decades of use as FDA-approved diagnostic agent with well-characterized pharmacology and safety - NIH-funded RCT (Sandler et al., NEJM 1999): no benefit of IV secretin for autism spectrum disorder (n=60, blinded, placebo-controlled) - Multiple subsequent RCTs confirmed no ASD benefit (Levy et al., 2003; Unis et al., 2002) - Diagnostic use: sensitivity and specificity for pancreatic exocrine insufficiency well-established - Safety profile excellent at diagnostic doses; hypersensitivity reactions rare ## Tier 2 — Emerging Human Mechanistic Data - Li et al. (Cell, 2018): postprandial secretin activates brown adipose tissue via gut-brain axis, increasing energy expenditure - fMRI studies show secretin modulates brain satiety centers following meal consumption - Human PET-CT confirms BAT activation correlates with postprandial secretin levels - Potential repositioning as a metabolic peptide is an active area of academic research ## Tier 3 — Preclinical - Secretin knockout mice show impaired postprandial satiety and reduced BAT activity - Secretin receptors in CNS suggest neuromodulatory roles beyond GI function - Anxiolytic effects in rodent behavioral models (elevated plus maze, open field) ## Evidence Gaps - No human trials for metabolic/weight management indication - Brown fat activation dose-response in humans not characterized - Long-term SC/IM administration never studied (only IV diagnostic boluses) - Practical application for biohacking/optimization is essentially zero at this time